Sam Smith on Improving Adherence in Patients with Breast Cancer
Sam Smith, PhD, from the University of Leeds, discusses strategies to improve adherence that is affected by menopausal symptoms.
Sam Smith, PhD, from the University of Leeds, discusses strategies to improve adherence that is affected by menopausal symptoms.
While attending the 2016 Meeting of the San Antonio Breast Cancer Symposium, Smith presented results of a trial studying how misattributing menopausal symptoms to tamoxifen therapy could create non-adherence in patients with breast cancer. Two interventions Smith suggests are cognitive behavior therapy and more accurate discussion with providers. If the patients are more aware of and better understand the symptoms, they are more likely to adhere to the treatment.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
